---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-058036"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T17:10:18.987292+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Protagonist Q1 net income $207.3M on $255M Takeda revenue; cash runway through Q4 2027

## Summary
- Net income of $207.3M ($3.26 diluted EPS) vs net loss of $33.7M in Q1 2023; revenue $255M from Takeda rusfertide license.
- Cash, equivalents & marketable securities $322.6M at March 31, 2024; extended runway through Q4 2027 including $300M upfront from Takeda.
- Phase 3 ICONIC LEAD and ICONIC TOTAL trials of JNJ-2113 in psoriasis completed enrollment; Phase 3 ICONIC ADVANCE studies ongoing.
- Expect to nominate oral IL-17 antagonist development candidate by end of 2024.
- Rusfertide VERIFY study top-line data expected by Q1 2025; potential deal value with Takeda up to $630M plus profit share/royalties.

## SEC filing metadata
- accession: 0001104659-24-058036
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465924058036/0001104659-24-058036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465924058036/tm2413671d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-058036
- JSON: https://secwatch.observer/filing/0001104659-24-058036.json
- Plain text: https://secwatch.observer/filing/0001104659-24-058036.txt

## Key facts
- Earnings Releases
  Protagonist Therapeutics, Inc reported first quarter ended March 31, 2024 results: revenue $255.0 million, net income $207,340 thousand, EPS $3.26 per diluted share.
  - Period: first quarter ended March 31, 2024
  - Revenue: $255.0 million
  - Net income: $207,340 thousand
  - EPS: $3.26 per diluted share
  - Result: reported results
  source text: ) Basic earnings (loss) per share $ 3.41 $ (0.67 ) Diluted earnings (loss) per share $ 3.26 $ (0.67 ) · License and Collaboration Revenue : License and collaboration revenue of $255.0 million for March 31, 2024 consisted of: (i) $254.1 million of the $300.0 million transaction price for the Takeda Collaboration Agreement allocated to the rusfertide license delivered
  evidence_url: https://www.sec.gov/Archives/edgar/data/1377121/000110465924058036/0001104659-24-058036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.